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Abstract 
This theme issue provides a timely overview on the current status of stem cell tracking with the 
nanoparticle-based contrast agents. 
 
Exogenous stem cell-based therapies hold 
promise and potential to revolutionize medicine by 
restoring tissue and organ function [1, 2]. To develop 
effective therapy, the location, distribution, persis-
tence, and functions of transplanted cells have to be 
evaluated [3]. Nanoparticle (NP)-based imaging 
technologies have the potential for qualitatively and 
quantitatively monitoring transplanted cells, which 
will facilitate prediction of treatment efficacy and re-
veal optimal transplantation conditions [4, 5]. In 
comparison to the traditional probes, NPs possess 
tunable sizes, shapes and compositions which yield 
desirable physical properties (i.e. electronic, magnetic, 
optical, and thermal properties). In addition, NPs 
possess an array of properties including magnetic and 
optical scattering, absorption or luminescence that can 
be readily measured with existing imaging modali-
ties. 
This special issue provides a sampling of the 
preparation and use of novel NP-based probes to 
track and study stem cells. First, Gu, Wu and their 
colleagues from Sichuan University examined this 
field from a perspective of materials chemistry [6]. 
They discussed the synthesis, surface coat-
ing/chemistry of NPs (especially magnetic NPs) that 
have been investigated for stem cell labeling for 
magnetic resonance imaging (MRI) tracking. Then 
Zhao and co-workers from the University of Califor-
nia-Irvine specifically summarized in vivo sensors that 
not only are able to track stem cells but also poten-
tially report their dynamic functions in the body [7]. 
These in vivo sensors therefore hold the potential to 
revolutionize our understanding of basic biology and 
our treatment of disease using stem cells. In their re-
view, they highlighted recent advances in the fields of 
in vivo electrochemical, optical, and MRI biosensors 
especially those using NPs (e.g., gold NPs, carbon 
nanotubes, and quantum dots). Song et al. from Car-
diff University then focused on the translational as-
pect of the topic [8]. After a brief recollection of the 
history of stem cell therapy and a concise comparison 
of the major imaging modalities in clinics, they fo-
cused on the clinically-preferred magnetic NPs and 
examined the major steps in the labeling and tracking 
of stem cells with magnetic NPs for the treatment of 
neurologic diseases. Then Mathiasen and Kastrup 
from Copenhagen University Hospital assessed this 
field from the clinical point-of-view [9]. By taking the 
coronary artery disease as an example, they summa-
rized the latest efforts in the clinic, where radionu-
clides, MRI, and reporter genes have been used to 
help understand and monitor the fate of transplanted 
stem cells. Once the labeling and tracking protocol is 
standardized, contrast agents are expected to be 
produced and distributed through industrial partners. 
Therefore, the perspectives from the industry is vital. 
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To that end, Wang et al. from the Hybrid Silica Tech-
nologies reviewed existing commercial NPs for three 
commonly used imaging modalities including fluo-
rescence imaging, MRI, and photoacoustic imaging 
[10]. Besides the scientific discussion about the tech-
nologies for preparing and utilizing NPs, they further 
listed challenges and expectations from industry for 
the development of new NP products for stem cell 
labeling and tracking. Finally, with the knowledge of 
success and limitations of NPs for stem cell labeling 
and tracking, Xia group (Georgia Institute of Tech-
nology) and Wang group (Washington University in 
St. Louis) presented exciting  gold nanocage-based 
contrast agents combined with two-photon micros-
copy and photoacoustic microscopy for the tracking 
of human mesenchymal stem cells [11]. 
In summary, the synergy between size, structure 
and physical properties of NPs makes them key 
players in revealing the fate and performance of stem 
cell therapy. Although there are several hurdles that 
still need to be addressed and solved before imple-
menting these platforms in the clinic, the successes 
and the clear promises provided in the above contri-
butions indicate that these platforms will advance our 
understanding of the fate of transplanted stem cells 
and enhance our ability to utilize them for helping the 
suffering patients. Clearly NPs have much to offer in 
stem cell research and therapy. 
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